they brought back synavive with a new wiz bang formulation as they needed something later stage to promote and dilute shares (raise money), that they did didn't they
then they brought back z160 with a new wiz bang formulation, big pharma did not want it, but they have something again p2 to what?, dilute and raise more money
it is really nothing more than survival at best,
reverse split a given, slow drift to 64-67 range, sec notice of rs then into the 50's
Synavive was simply re-formulated to be a time release in order to reduce complications from severe headaches. On that front, it worked. It just so happened that Synavive wasn't a better option for RA than prednisolone, so its chances of making it to the market were non-existent.
Z-160 was re-formulated to fix bioavailability issues. We know that the drug is significantly more bioavailable now, based on studies. We also know that the MoA works, based on prialt. Lastly, the drug worked extremely well in animal models, which has been a very positive indicator for other pain meds on the market.
Hwsi, another thing needs to mention is they found Z160 had analgesic effect if concentration was above 400ng during Merck trial, now with increased bioavailability that conecentration is easy to reach!
is the pps not slowly drifting downward? did the pr of z944 get the stock to go up? is the reverse split going to happen in the next few weeks, has institutional investing not been going downward? a moron would be someone that thinks this will magically jump above a dollar in the next few weeks, going in wrong direction is it not?